Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Spp1 (osteopontin) promotes TGFβ processing in fibroblasts of dystrophin deficient muscles through matrix metalloproteinases.

Kramerova I, Kumagai-Cresse C, Ermolova N, Mokhonova E, Marinov M, Capote J, Becerra D, Quattrocelli M, Crosbie RH, Welch E, McNally EM, Spencer MJ.

Hum Mol Genet. 2019 Aug 14. pii: ddz181. doi: 10.1093/hmg/ddz181. [Epub ahead of print]

PMID:
31411676
2.

Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy.

Parvatiyar MS, Brownstein AJ, Kanashiro-Takeuchi RM, Collado JR, Dieseldorff Jones KM, Gopal J, Hammond KG, Marshall JL, Ferrel A, Beedle AM, Chamberlain JS, Renato Pinto J, Crosbie RH.

JCI Insight. 2019 Apr 30;5. pii: 123855. doi: 10.1172/jci.insight.123855.

3.

Myogenic Akt signaling attenuates muscular degeneration, promotes myofiber regeneration and improves muscle function in dystrophin-deficient mdx mice.

Kim MH, Kay DI, Rudra RT, Chen BM, Hsu N, Izumiya Y, Martinez L, Spencer MJ, Walsh K, Grinnell AD, Crosbie RH.

Hum Mol Genet. 2011 Apr 1;20(7):1324-38. doi: 10.1093/hmg/ddr015. Epub 2011 Jan 18.

4.

Altered calcium pump and secondary deficiency of gamma-sarcoglycan and microspan in sarcoplasmic reticulum membranes isolated from delta-sarcoglycan knockout mice.

Solares-Pérez A, Alvarez R, Crosbie RH, Vega-Moreno J, Medina-Monares J, Estrada FJ, Ortega A, Coral-Vazquez R.

Cell Calcium. 2010 Jul;48(1):28-36. doi: 10.1016/j.ceca.2010.06.003. Epub 2010 Jul 16.

5.

Emerging genetic therapies to treat Duchenne muscular dystrophy.

Nelson SF, Crosbie RH, Miceli MC, Spencer MJ.

Curr Opin Neurol. 2009 Oct;22(5):532-8. doi: 10.1097/WCO.0b013e32832fd487. Review.

6.

Myogenic Akt signaling upregulates the utrophin-glycoprotein complex and promotes sarcolemma stability in muscular dystrophy.

Peter AK, Ko CY, Kim MH, Hsu N, Ouchi N, Rhie S, Izumiya Y, Zeng L, Walsh K, Crosbie RH.

Hum Mol Genet. 2009 Jan 15;18(2):318-27. doi: 10.1093/hmg/ddn358. Epub 2008 Nov 4.

7.

Sarcospan reduces dystrophic pathology: stabilization of the utrophin-glycoprotein complex.

Peter AK, Marshall JL, Crosbie RH.

J Cell Biol. 2008 Nov 3;183(3):419-27. doi: 10.1083/jcb.200808027.

8.

Direct interaction of Gas11 with microtubules: implications for the dynein regulatory complex.

Bekker JM, Colantonio JR, Stephens AD, Clarke WT, King SJ, Hill KL, Crosbie RH.

Cell Motil Cytoskeleton. 2007 Jun;64(6):461-73.

PMID:
17366626
9.

Disrupted mechanical stability of the dystrophin-glycoprotein complex causes severe muscular dystrophy in sarcospan transgenic mice.

Peter AK, Miller G, Crosbie RH.

J Cell Sci. 2007 Mar 15;120(Pt 6):996-1008. Epub 2007 Feb 20.

10.

Structural and functional analysis of the sarcoglycan-sarcospan subcomplex.

Miller G, Wang EL, Nassar KL, Peter AK, Crosbie RH.

Exp Cell Res. 2007 Feb 15;313(4):639-51. Epub 2006 Dec 14.

11.

Over-expression of Microspan, a novel component of the sarcoplasmic reticulum, causes severe muscle pathology with triad abnormalities.

Miller G, Peter AK, Espinoza E, Heighway J, Crosbie RH.

J Muscle Res Cell Motil. 2006;27(8):545-58. Epub 2006 Jul 4.

PMID:
16823602
12.

Hypertrophic response of Duchenne and limb-girdle muscular dystrophies is associated with activation of Akt pathway.

Peter AK, Crosbie RH.

Exp Cell Res. 2006 Aug 1;312(13):2580-91. Epub 2006 May 22.

PMID:
16797529
13.

Expanding the role of the dynein regulatory complex to non-axonemal functions: association of GAS11 with the Golgi apparatus.

Colantonio JR, Bekker JM, Kim SJ, Morrissey KM, Crosbie RH, Hill KL.

Traffic. 2006 May;7(5):538-48.

14.

Specific and potent RNA interference in terminally differentiated myotubes.

Yi CE, Bekker JM, Miller G, Hill KL, Crosbie RH.

J Biol Chem. 2003 Jan 10;278(2):934-9. Epub 2002 Nov 5.

15.

Loss of sarcolemma nNOS in sarcoglycan-deficient muscle.

Crosbie RH, Barresi R, Campbell KP.

FASEB J. 2002 Nov;16(13):1786-91.

PMID:
12409321
16.

Characterization of aquaporin-4 in muscle and muscular dystrophy.

Crosbie RH, Dovico SA, Flanagan JD, Chamberlain JS, Ownby CL, Campbell KP.

FASEB J. 2002 Jul;16(9):943-9.

PMID:
12087055
17.

NO vascular control in Duchenne muscular dystrophy.

Crosbie RH.

Nat Med. 2001 Jan;7(1):27-9.

PMID:
11135610
18.

Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain.

Crawford GE, Faulkner JA, Crosbie RH, Campbell KP, Froehner SC, Chamberlain JS.

J Cell Biol. 2000 Sep 18;150(6):1399-410.

19.

Molecular and genetic characterization of sarcospan: insights into sarcoglycan-sarcospan interactions.

Crosbie RH, Lim LE, Moore SA, Hirano M, Hays AP, Maybaum SW, Collin H, Dovico SA, Stolle CA, Fardeau M, Tomé FM, Campbell KP.

Hum Mol Genet. 2000 Aug 12;9(13):2019-27.

PMID:
10942431
20.

Biosynthesis of dystroglycan: processing of a precursor propeptide.

Holt KH, Crosbie RH, Venzke DP, Campbell KP.

FEBS Lett. 2000 Feb 18;468(1):79-83.

21.

Membrane targeting and stabilization of sarcospan is mediated by the sarcoglycan subcomplex.

Crosbie RH, Lebakken CS, Holt KH, Venzke DP, Straub V, Lee JC, Grady RM, Chamberlain JS, Sanes JR, Campbell KP.

J Cell Biol. 1999 Apr 5;145(1):153-65.

22.

Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice.

Duclos F, Straub V, Moore SA, Venzke DP, Hrstka RF, Crosbie RH, Durbeej M, Lebakken CS, Ettinger AJ, van der Meulen J, Holt KH, Lim LE, Sanes JR, Davidson BL, Faulkner JA, Williamson R, Campbell KP.

J Cell Biol. 1998 Sep 21;142(6):1461-71.

23.

Caveolin-3 is not an integral component of the dystrophin glycoprotein complex.

Crosbie RH, Yamada H, Venzke DP, Lisanti MP, Campbell KP.

FEBS Lett. 1998 May 8;427(2):279-82.

24.

mdx muscle pathology is independent of nNOS perturbation.

Crosbie RH, Straub V, Yun HY, Lee JC, Rafael JA, Chamberlain JS, Dawson VL, Dawson TM, Campbell KP.

Hum Mol Genet. 1998 May;7(5):823-9.

PMID:
9536086
25.

Sarcospan, the 25-kDa transmembrane component of the dystrophin-glycoprotein complex.

Crosbie RH, Heighway J, Venzke DP, Lee JC, Campbell KP.

J Biol Chem. 1997 Dec 12;272(50):31221-4.

26.

Muscular dystrophy. Utrophin to the rescue.

Campbell KP, Crosbie RH.

Nature. 1996 Nov 28;384(6607):308-9. No abstract available.

PMID:
8934508
27.

Flexation of caldesmon: effect of conformation on the properties of caldesmon.

Crosbie RH, Chalovich JM, Reisler E.

J Muscle Res Cell Motil. 1995 Oct;16(5):509-18.

PMID:
8567938
28.

Structural connectivity in actin: effect of C-terminal modifications on the properties of actin.

Crosbie RH, Miller C, Cheung P, Goodnight T, Muhlrad A, Reisler E.

Biophys J. 1994 Nov;67(5):1957-64.

29.

Caldesmon, N-terminal yeast actin mutants, and the regulation of actomyosin interactions.

Crosbie RH, Miller C, Chalovich JM, Rubenstein PA, Reisler E.

Biochemistry. 1994 Mar 22;33(11):3210-6.

PMID:
8136356
30.

Interaction of caldesmon and myosin subfragment 1 with the C-terminus of actin.

Crosbie RH, Chalovich JM, Reisler E.

Biochem Biophys Res Commun. 1992 Apr 15;184(1):239-45.

PMID:
1567431

Supplemental Content

Loading ...
Support Center